|
(P2130) |
Post-translational modification of angiotensin II by vitamin B6 for hypertension treatment in low-income countries |
| |
|
M. Lellig, J. Muñoz-Castañeda, J. Hermann, H. Noels, M. Rodríguez, J. Jankowski, V. Jankowski (Aachen; Cordoba, ES) |
|
(P2131) |
Targeted Antibiotic Modulation of the Intestinal Microbiome Modulates Hypertensive End Organ Damage |
| |
|
M. I. Wimmer, V. Vecera, S. Kedziora, O. Potapenko, A. Rauch, T. U. P. Bartolomaeus, N. Haase, S. K. Forslund, D. N. Müller, H. Bartolomaeus, N. Wilck (Berlin) |
|
(P2132) |
Longitudinal Analysis of Heart Failure Development in a Novel Rat Model – Additive Value of a Hypertensive Stimulus |
| |
|
A. Thiele, H. Bartolomaeus, N. Haase, A. Heuser, D. N. Müller, R. Dechend, N. Wilck (Berlin) |
|
(P2133) |
CRIP1 as a novel player in hypertension-related inflammatory signaling pathways |
| |
|
T. Tong, J. Duque Escobar, O. Schweigert, T. Zeller, for the study group: DZHK (Hamburg) |
|
(P2135) |
Association of hydrochlorothiazide treatment compared to alternative diuretics with overall and skin cancer risk: A propensity-matched cohort study |
| |
|
F. Götzinger, T. Wilke, F. Hardtstock, J. Krieger, U. Maywald, M. Kunz, L. Lauder, C. Ukena, M. Schulz, F. Mahfoud, M. Böhm (Homburg/Saar, Wismar, Mannheim, Hamburg, Berlin) |
|
(P2136) |
Blood Pressure Reduction after Renal Denervation in Patients with or without Chronic Kidney Disease: The ERLANGER experience |
| |
|
M. Günes-Altan, A. Schmid, C. Ott, A. Bosch, M. Schiffer, M. Uder, R. E. Schmieder, D. Kannenkeril (Erlangen) |
|
(P2137) |
Patienten mit vorbestehender arterieller Hypertonie im Schock haben nach 24 Stunden eine signifikant schlechtere sublinguale Mikrozirkulation |
| |
|
R. R. Bruno, S. N. Binnebößel, G. Wolff, M. Kelm, C. Jung (Düsseldorf) |